Evidence map›Paper›PMID 39000472›Full record

ArticleInternational journal of molecular sciences2024

Cyclo(l-Pro-l-Tyr) Isolated from the Human Skin Commensal

Yuika Sekino, Ikuya Yamamoto, Masahiro Watanabe, Kouji Kuramochi, Yuuki Furuyama

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuika SekinoDepartment of Applied Bioscience, Tokyo University of Science, 2641 Yamazaki, Noda 278-8519, Chiba, Japan.
Ikuya YamamotoDepartment of Applied Bioscience, Tokyo University of Science, 2641 Yamazaki, Noda 278-8519, Chiba, Japan.
Masahiro WatanabeDepartment of Applied Bioscience, Tokyo University of Science, 2641 Yamazaki, Noda 278-8519, Chiba, Japan.
Kouji KuramochiDepartment of Applied Bioscience, Tokyo University of Science, 2641 Yamazaki, Noda 278-8519, Chiba, Japan.ORCID 0000-0003-0571-9703
Yuuki FuruyamaDepartment of Applied Bioscience, Tokyo University of Science, 2641 Yamazaki, Noda 278-8519, Chiba, Japan.ORCID 0000-0003-0851-5204

Funding

JSPS KAKENHI 22K14814
6 · The paper itself

Abstract

Melanin is produced by melanocytes to protect human skin from harmful ultraviolet radiation. During skin cell renewal, melanin and dead skin cells are disposed of. However, prolonged exposure to ultraviolet rays or aging can disturb this cycle, leading to skin hyperpigmentation due to melanin accumulation. Tyrosinase is a crucial enzyme involved in melanin biosynthesis. Although various compounds, including tyrosine inhibitors, that counteract melanin accumulation have been reported, some, such as hydroquinone, are toxic and can cause vitiligo. Meanwhile, the skin is the largest organ and the outermost layer of the immune system, containing a diverse range of bacteria that produce low-toxicity compounds. In the current study, we aim to identify metabolites produced by skin microbiota that inhibit tyrosinase. Specifically, mushroom tyrosinase served as the study model. Following commensal skin bacteria screening,

Indexed as

CorynebacteriumMonophenol MonooxygenaseSkinAgaricalesEnzyme InhibitorsHumansMelaninsMolecular Docking SimulationPeptides, CyclicEnzyme InhibitorsMelaninsMonophenol MonooxygenasePeptides, CyclicCorynebacterium tuberculostearicumcyclic dipeptideskin microbiotatyrosinase inhibitor

Identifiers

PMID39000472
PMCPMC11242031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.